Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Expected to Post Earnings of -$0.19 Per Share

Analysts expect Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Rating) to announce ($0.19) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Greenwich LifeSciences’ earnings. The company is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Greenwich LifeSciences will report full-year earnings of ($0.72) per share for the current financial year. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Greenwich LifeSciences.

Separately, Zacks Investment Research upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research note on Friday.

In related news, CEO Snehal Patel bought 5,500 shares of the company’s stock in a transaction dated Friday, February 11th. The shares were acquired at an average price of $19.80 per share, for a total transaction of $108,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders acquired 12,300 shares of company stock valued at $238,581 in the last ninety days. 68.93% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the company. OLD Mission Capital LLC purchased a new stake in Greenwich LifeSciences during the 3rd quarter worth approximately $287,000. Tibra Equities Europe Ltd purchased a new stake in Greenwich LifeSciences during the 3rd quarter worth approximately $496,000. Jane Street Group LLC increased its stake in Greenwich LifeSciences by 25.2% during the 3rd quarter. Jane Street Group LLC now owns 6,891 shares of the company’s stock worth $269,000 after buying an additional 1,388 shares during the period. D. E. Shaw & Co. Inc. purchased a new stake in Greenwich LifeSciences during the 4th quarter worth approximately $254,000. Finally, UBS Group AG increased its stake in Greenwich LifeSciences by 467.1% during the 3rd quarter. UBS Group AG now owns 4,310 shares of the company’s stock worth $168,000 after buying an additional 3,550 shares during the period. 6.25% of the stock is currently owned by institutional investors and hedge funds.

Greenwich LifeSciences stock opened at $17.16 on Friday. The stock has a 50-day moving average price of $19.98. Greenwich LifeSciences has a 1-year low of $15.52 and a 1-year high of $48.96.

About Greenwich LifeSciences (Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery.

Read More

Get a free copy of the Zacks research report on Greenwich LifeSciences (GLSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.